AU2017368135A1 - Tyrosine derivatives and compositions comprising them - Google Patents

Tyrosine derivatives and compositions comprising them Download PDF

Info

Publication number
AU2017368135A1
AU2017368135A1 AU2017368135A AU2017368135A AU2017368135A1 AU 2017368135 A1 AU2017368135 A1 AU 2017368135A1 AU 2017368135 A AU2017368135 A AU 2017368135A AU 2017368135 A AU2017368135 A AU 2017368135A AU 2017368135 A1 AU2017368135 A1 AU 2017368135A1
Authority
AU
Australia
Prior art keywords
cancer
tyrosine
methyl
composition
propanoate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2017368135A
Other languages
English (en)
Inventor
Steven Hoffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tyme Inc
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of AU2017368135A1 publication Critical patent/AU2017368135A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2017368135A 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them Abandoned AU2017368135A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/365,120 2016-11-30
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
PCT/US2017/063865 WO2018102506A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Publications (1)

Publication Number Publication Date
AU2017368135A1 true AU2017368135A1 (en) 2019-06-13

Family

ID=60703174

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017368135A Abandoned AU2017368135A1 (en) 2016-11-30 2017-11-30 Tyrosine derivatives and compositions comprising them

Country Status (12)

Country Link
EP (1) EP3548086A1 (enExample)
JP (2) JP2019536783A (enExample)
KR (1) KR20190089191A (enExample)
CN (1) CN110062633A (enExample)
AU (1) AU2017368135A1 (enExample)
BR (1) BR112019011033A2 (enExample)
CA (1) CA3045110A1 (enExample)
EA (1) EA201991305A1 (enExample)
IL (1) IL266840A (enExample)
MX (1) MX2019006326A (enExample)
PH (1) PH12019501186A1 (enExample)
WO (1) WO2018102506A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 α-甲基酪氨酸或其衍生物的用途
JP2022532210A (ja) 2019-05-14 2022-07-13 タイム，インコーポレーテッド がんを処置する組成物および方法
CA3157334A1 (en) * 2019-11-07 2021-05-14 Miguel Angel MOLINA-VILLA Methods and compositions for use of growth factor antibodies in combination with non-tyrosine targeting kinase inhibitors
AU2021207666A1 (en) * 2020-01-17 2022-09-01 Tyme, Inc. Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2005072061A2 (en) * 2004-02-02 2005-08-11 Biosight Ltd. Conjugates for cancer therapy and diagnosis
KR101653182B1 (ko) * 2006-04-19 2016-09-01 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 세포 영상화 및 치료를 위한 조성물 및 방법
JP5688840B2 (ja) * 2007-09-10 2015-03-25 ボストン バイオメディカル， インコーポレイテッド 新規のＳｔａｔ３経路阻害剤及び癌幹細胞阻害剤
NZ721280A (en) * 2012-01-17 2017-08-25 Tyme Inc Pharmaceutical compositions and methods for treating cancer
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
JP2019536783A (ja) 2019-12-19
IL266840A (en) 2019-07-31
PH12019501186A1 (en) 2020-02-10
JP2022153587A (ja) 2022-10-12
MX2019006326A (es) 2019-07-12
CA3045110A1 (en) 2018-06-07
CN110062633A (zh) 2019-07-26
EP3548086A1 (en) 2019-10-09
BR112019011033A2 (pt) 2019-10-15
KR20190089191A (ko) 2019-07-30
WO2018102506A1 (en) 2018-06-07
EA201991305A1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
US20220313642A1 (en) Tyrosine derivatives and compositions comprising them
US8481498B1 (en) Pharmaceutical compositions and methods
US10307465B2 (en) Pharmaceutical compositions and methods
CA2862689C (en) .alpha.-methyl-dl-tyrosine, compositions, kits, combinations and use thereof for the treatment of cancer or for reducing cell proliferation
JP2022153587A (ja) チロシン誘導体及びそれらを含む組成物
US10507198B2 (en) Pharmaceutical compositions and methods
US20200345753A1 (en) Pharmaceutical compositions for the treatment of cancer
CA3040922A1 (en) Pharmaceutical compositions and methods for the treatment of cancer
US20210106549A1 (en) Pharmaceutical compositions and methods
US11103559B2 (en) Pharmaceutical compositions and methods
US20210386832A1 (en) Pharmaceutical Compositions And Methods

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted